MARLBOROUGH, Mass., Jan. 24, 2011 /PRNewswire/ — CardioFocus
announced that two “live cases” using its Endoscopic Ablation
System were recently conducted. The first live case was a satellite
transmission performed at Centro Cardiologico Monzino in Milan,
Italy; broadcast to the 16th Annual Boston Symposium on Atrial
Fibrillation in Boston, MA. Several pioneers in the treatment of
atrial fibrillation served as moderators for this exciting
educational presentation, providing perspective on ablation
procedures designed to isolate pulmonary veins.
The second live case was performed at St. Georg Hospital, in
Hamburg, Germany, by Prof. Karl-Heinz Kuck. Both cases demonstrate
the continued interest of leading catheter ablation experts to gain
a real time view of the anatomy they are treating to enable durable
PV isolation.
Stephen Sagon, CEO of CardioFocus said, “These back-to-back live
cases provide CardioFocus with a unique opportunity to be seen by
clinicians from around the world. Now that we have CE Mark approval
for the latest version of our equipment, we have received requests
from multiple, well-respected international arrhythmia centers. We
plan to continue our highly disciplined launch of the Endoscopic
Ablation System at key European sites in 2011.”
The acute isolation rate of pulmonary veins has been reported by
CardioFocus clinical investigators at over 99% in peer reviewed
articles. While nearly all of the pulmonary veins were isolated
during the procedure, 78% of veins were isolated on the very first
attempt. Chronic PV isolation was reported to approach 90% when
assessed at 3 months. According to Burke Barrett, CardioFocus Vice
President of Clinical and Regulatory Affairs, “We expect more
scientific studies and further presentations on our Endoscopic
Ablation System technology throughout the year, including the
company’s US IDE pivotal study in the first half of
2011.”
Two years after the initiation of clinical research
‘/>”/>
